The cyclic GMP-AMP synthase (cGAS) – stimulator of interferon genes (STING) pathway plays a key role in detecting pathogens in cells and activating downstream immune responses. It acts as the central cytosolic sensor for microbial nucleic acids and is involved in the production of type I interferons during viral or bacterial infections. Recent advances in understanding cGAS-STING signaling has enabled the development of novel therapies targeting this pathway.

The Global cGAS STING Pathway Market is estimated to be valued at USD 0.71 Billion in 2024 and is expected to reach USD 3.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 25.3% from 2024 to 2031.
Key players operating in the cGAS STING pathway are Gilead Sciences, Pfizer, Merck, Invivogen, Roche, etc.

Key Takeaways

Key players: Gilead Sciences is one of the major players in this market with its vaccine candidates targeting STING pathway. Pfizer and Merck are also investing heavily in STING pathway modulators to treat cancers and infectious diseases.
Small biotech firms like Invivogen provide reagents and tools to study cGAS-STING signaling mechanism. Pharma giants like Roche are also evaluating cGAS-STING Pathway agonists in clinical trials.

Get More Insights - cGAS STING Pathway Market